
## Jenna Gregory

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8778213/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nature Communications, 2018, 9, 347.	12.8	151
2	Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. Nature Communications, 2022, 13, 135.	12.8	97
3	Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathologica, 2021, 141, 257-279.	7.7	76
4	The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Human Molecular Genetics, 2016, 25, 3908-3924.	2.9	72
5	TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurology, 2018, 18, 90.	1.8	63
6	Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 149-157.	1.9	54
7	The Aggregation and Neurotoxicity of TDP-43 and Its ALS-Associated 25 kDa Fragment Are Differentially Affected by Molecular Chaperones in Drosophila. PLoS ONE, 2012, 7, e31899.	2.5	53
8	Clusterin protects neurons against intracellular proteotoxicity. Acta Neuropathologica Communications, 2017, 5, 81.	5.2	47
9	Genetics of Amyotrophic Lateral Sclerosis. Current Genetic Medicine Reports, 2020, 8, 121-131.	1.9	41
10	Dysregulation of AMPA receptor subunit expression in sporadic ALS postâ€mortem brain. Journal of Pathology, 2020, 250, 67-78.	4.5	36
11	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Communications, 2021, 3, fcab242.	3.3	32
12	Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2020, 46, 441-457.	3.2	25
13	Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Brain Communications, 2019, 1, fcz009.	3.3	20
14	<scp>NLRP3</scp> inflammasome as a key molecular target underlying cognitive resilience in amyotrophic lateral sclerosis. Journal of Pathology, 2022, 256, 262-268.	4.5	17
15	Probing TDP-43 condensation using an in silico designed aptamer. Nature Communications, 2022, 13, .	12.8	16
16	Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2020, 46, 255-263.	3.2	15
17	Improved detection of RNA foci in C9orf72 amyotrophic lateral sclerosis post-mortem tissue using BaseScopeâ"¢ shows a lack of association with cognitive dysfunction. Brain Communications, 2020, 2, fcaa009.	3.3	12
18	Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: a systematic review of in vitro studies. Brain Communications, 2020, 2, fcaa121.	3.3	10

Jenna Gregory

#	Article	IF	CITATIONS
19	40 Years of CSF Toxicity Studies in ALS: What Have We Learnt About ALS Pathophysiology?. Frontiers in Molecular Neuroscience, 2021, 14, 647895.	2.9	10
20	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open, 2022, 12, e064173.	1.9	10
21	Could an Impairment in Local Translation of mRNAs in Glia be Contributing to Pathogenesis in ALS?. Frontiers in Molecular Neuroscience, 2019, 12, 124.	2.9	9
22	Therapeutic Targeting of Proteostasis in Amyotrophic Lateral Sclerosis—a Systematic Review and Meta-Analysis of Preclinical Research. Frontiers in Neuroscience, 2020, 14, 511.	2.8	7
23	An epidemiological profile of dysarthria incidence and assistive technology use in the living population of people with MND in Scotland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 116-122.	1.7	6
24	TDP-43 proteinopathy in oligodendrocytes revealed using an induced pluripotent stem cell model. Brain Communications, 2021, 3, fcab255.	3.3	4
25	Dysregulation in Subcellular Localization of Myelin Basic Protein mRNA Does Not Result in Altered Myelination in Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2021, 15, 705306.	2.8	3
26	Protocol for a systematic review and metaâ€analysis of experimental models of amyotrophic lateral sclerosis. Evidence-based Preclinical Medicine, 2016, 3, 17-19.	0.9	2